Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type- `0 q3 f2 \" ` \
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 $ V! [# b7 j u5 y( @/ R# {
+ Author Affiliations6 {) R+ Z8 u& c
+ G% @1 y. ^8 F/ g/ m/ [+ P& |( J1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan + y9 d2 v" V0 O! A4 P$ g; {
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
2 F( T8 c/ X6 q& E4 G2 Y) @3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan # V D& Q9 H: ?. Q* H( i
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
7 C) A1 b: z" w( F8 d* g, T; Q5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
) L( ], I( A- `! f7 a6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan : z+ w# m' J( U0 k8 z3 B6 U
7Kinki University School of Medicine, Osaka 589-8511, Japan 7 f% B- L/ H# c, l
8Izumi Municipal Hospital, Osaka 594-0071, Japan : l" D1 {! r' ~6 h. c9 i
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan " o% D& }( V0 _ ^4 l
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ; Q; B# q/ a. ]/ w$ E" C* n6 T
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
; s+ }, i+ G" r% j( f: _# [7 C: G; v+ I/ l# E$ c; N$ H4 l
|